Clik here to view.
Dexcom touts continuous glucose monitoring for Type II diabetes patients
Dexcom (NSDQ:DXCM) touted data today showing that people with Type II diabetes who are using multiple daily injections of insulin can benefit from the use of continuous glucose monitoring. Those in the...
View ArticleClik here to view.
Novartis launches MS study using data collected from smartphones
Novartis (NYSE:NVS) said today that it is launching a research study to better understand the daily challenges facing people with multiple sclerosis. The study is designed to collect data from physical...
View ArticleClik here to view.
Omeros closes $68m public offering
Biopharma company Omeros (NSDQ:OMER) said that it closed a $68.3 million underwritten public offering last week, selling 3 million shares of its common stock at $22.75 apiece. After deducting fees and...
View ArticleClik here to view.
Sirtex swings to a loss after ‘challenging’ year
Shares in Australian cancer treatment developer Sirtex Medical (ASX:SRX) plunged more than 15% yesterday after the company posted a net loss of -A$26.9 million in 2016, compared to a profit of A$54...
View ArticleClik here to view.
Diabetes app developer DarioHealth closes $5m private placements
Digital health company DarioHealth (NSDQ:DRIO) said today that it closed a $5 million private placement with new and existing investors for shares of the company’s common stock and shares of the...
View ArticleClik here to view.
Bonti kicks off Ph2 trial for neurotoxin pain-reliever
Privately-held biotech Bonti said today that it launched the Lantern clinical program, evaluating its intramuscular neurotoxin injection as a non-opioid pain reliever. The first clinical trial,...
View ArticleClik here to view.
Cel-Sci raises $3.5m for head and neck cancer immunotherapy
Cel-Sci (NYSE:CVM) said today that it inked an agreement with institutional investors for a $3.5 million registered direct offering. The company said it plans to offer 1.75 million shares of common...
View ArticleClik here to view.
Tandem Diabetes launches t:lock connector for its insulin pumps
Tandem Diabetes Care (NSDQ:TNDM) said today that it launched the t:lock Connector for its insulin pump cartridges and infusion sets. The connector, which is produced and supplied by Unomedical, has a...
View ArticleClik here to view.
Propeller Health, GSK expand collaboration for connected inhaler
Propeller Health and GlaxoSmithKline (NYSE:GSK) said today that the two companies are planning to commercialize GSK’s Ellipta inhaler with Propeller’s clip-on medication sensor and software platform....
View ArticleClik here to view.
Titan wins FDA nod to study Parkinson’s implant
Titan Pharmaceuticals (NSDQ:TTNP) said today that the FDA cleared the investigational new drug application for its ropinirole implant designed to treat the symptoms of Parkinson’s disease. The Phase...
View ArticleClik here to view.
Contract manufacturer Althea launches sterile vial filling line
Contract development & manufacturing organization Althea, an Ajinomoto company, announced today the launch of a new, high-performance sterile vial filling line. The Optima VFVM 7000 aseptic fill...
View ArticleClik here to view.
Federal judge dismisses faulty birth control suit against Merck
A Maine federal judge tossed out a woman’s lawsuit against Merck (NYSE:MRK), after she claimed that the company’s Nexplanon birth control implant allegedly failed to keep her from becoming pregnant....
View ArticleClik here to view.
FDA clears Nordisk’s Victoza as only Type II diabetes drug to cut cardio risks
The FDA approved a new indication for Novo Nordisk‘s (NYSE:NVO) Victoza liraglutide injection, clearing it as the only Type II diabetes medication indicated to reduce the risk of cardiovascular...
View ArticleClik here to view.
‘Body-on-a-chip’ device screens human heart cells for drug toxicity
Researchers at Kyoto University‘s Institute for Integrated Cell-Material Sciences have developed a ‘body-on-a-chip’ device that can evaluate the side-effects of drugs on human cells, according to a...
View ArticleClik here to view.
One Drop touts effects of diabetes management mobile app
One Drop touted data today from a retrospective study of people with Type I and Type II diabetes using its mobile diabetes management app. The data, which were published yesterday in JMIR Diabetes,...
View ArticleClik here to view.
Gilead expands into cell therapy with $11.9B Kite Pharma purchase
Taking a plunge into the cell therapy arena, Gilead Sciences (NSDQ:GILD) said today that it has inked an $11.9 billion deal to acquire Kite Pharma (NSDQ:KITE). The deal, which was unanimously approved...
View ArticleClik here to view.
Tandem Diabetes wins FDA nod for insulin pump with Dexcom’s CGM
Tandem Diabetes Care (NSDQ:TNDM) said today that the FDA approved its t:slim X2 insulin pump with Dexcom‘s (NSDQ:DXCM) G5 mobile continuous glucose monitor. The regulatory win makes the device the...
View ArticleClik here to view.
Bard lands new indication for its drug-coated balloon
C. R. Bard(NYSE:BCR) said today that its Lutonix 035 drug-coated balloon PTA catheter won premarket approval from the FDA and is available in the U.S. The company’s Lutonix 035 device is the first...
View ArticleClik here to view.
Xarelto, aspirin combo reduces risk of cardiovascular events in pivotal Ph3...
Johnson & Johnson (NYSE:JNJ) subsidiary Janssen touted data today from a pivotal Phase III trial showing that Xarelto plus aspirin reduced the risk of major cardiovascular events in patients with...
View ArticleClik here to view.
Biotronik’s Orsiro drug-eluting stent tops Abbott’s Xience in study
Biotronik said today that its Orsiro drug-eluting stent beat Abbott‘s (NYSE:ABT) Xience DES in a trial comparing the target lesion failure rates of both devices. The data, which were presented at the...
View Article